RFC2

Across TCGA pan-cancer cohorts, RFC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RFC2 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RFC2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RFC2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where RFC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.380	1.000	.008	18	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.587	.007	11	view →
CCRCC	DFS	Tertile	III,IV	0.530	0.847	.021	8	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
LUAD	DFS	Tertile	III,IV	0.838	0.426	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RFC2–HNSC (OS)

Open the HNSC breakdown →